The prevalence of hyperkalemia in the United States

Betts, Keith A.; Woolley, J. Michael; Mu, Fan; McDonald, Evangeline; Tang, Wenxi; Wu, Eric Q.

doi:10.1080/03007995.2018.1433141

Cited by 80 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Addison's disease or adrenal enzyme deficiencies) can also be contributing factors 3,8,9 . Along with renal impairment, heart failure and diabetes mellitus can also increase the risk of hyperkalemia 2,4,[10][11][12] . The reduced cardiac output of patients with heart failure may compromise renal perfusion and increase the risk of hyperkalemia 13 , while diabetic insulin deficiency may raise serum potassium concentrations due to impairment in transcellular potassium transport 14 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence and economic burden of hyperkalemia in the United States Medicare population

Betts

Woolley

et al. 2020

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

Objective: To estimate the prevalence and economic burden of hyperkalemia in the United States (US) Medicare population. Methods: Patients were selected from a 5% random sample of Medicare beneficiaries (01 January 2010-31 December 2014) to estimate the prevalence and economic burden of hyperkalemia. The prevalence for each calendar year was calculated as the number of patients with hyperkalemia divided by the total number of eligible patients per year. To estimate the economic burden of hyperkalemia, patients with hyperkalemia (cases) were matched 1:1 to patients without hyperkalemia (controls) on age group, chronic kidney disease [CKD] stage, dialysis treatment, and heart failure. The incremental 30-day and 1-year resource utilization and costs (2016 USD) associated with hyperkalemia were estimated. Results: The estimated prevalence of hyperkalemia was 2.6-2.7% in the overall population and 8.9-9.3% among patients with CKD and/or heart failure. Patients with hyperkalemia had higher 1-year rates of inpatient admissions (1.28 vs. 0.44), outpatient visits (30.48 vs. 23.88), emergency department visits (2.01 vs. 1.17), and skilled nursing facility admissions (0.36 vs. 0.11) than the matched controls (all p < .001

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and economic burden of hyperkalemia in the United States Medicare population

Betts

Woolley

et al. 2020

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple recent real-world evidence studies (ie, prospective or retrospective database analyses) support the burden of hyperkalemia, 6,7,[91][92][93][94][95][96][97][98][99][100] and actual-use data on the agents used to treat hyperkalemia are accruing. 101,102 Available real-world data indicate that SPS is associated with a high incidence of severe gastrointestinal adverse events, including reports of colonic necrosis and gastrointestinal injury, particularly when combined with sorbitol and in patients with CKD.…”

Section: Real-world Experience With K þ Bindersmentioning

confidence: 99%

Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis

Palmer

2020

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Hyperkalemia is a potentially life-threatening complication of chronic kidney disease (CKD). The management of CKD requires balancing the benefits of specific treatments, which may exacerbate the potential for hyperkalemia, with the risks of hyperkalemia itself. Renin-angiotensin-aldosterone system (RAAS) inhibitors, which slow CKD progression and improve cardiovascular outcomes, are often discontinued if hyperkalemia develops. Patients with hyperkalemia are frequently advised to restrict dietary potassium (K þ), depriving these patients of many heart-healthy foods. Patients receiving hemodialysis are particularly susceptible to hyperkalemia during long interdialytic intervals, and managing this risk without causing hypokalemia can be challenging. Recently, 2 K þ-binding agents were approved for the treatment of hyperkalemia: sodium zirconium cyclosilicate and patiromer. These agents offer alternatives to sodium polystyrene sulfonate, which is associated with serious gastrointestinal adverse effects. For this review, PubMed was searched for English-language articles published in 2014-2018 using the terms patiromer, sodium zirconium cyclosilicate, sodium polystyrene sulfonate, hyperkalemia, renin-angiotensin-aldosterone, diet, and dialysis. In randomized controlled studies of patients with hyperkalemia, sodium zirconium cyclosilicate and patiromer effectively reduced serum K þ and were generally well tolerated. Furthermore, patients in these studies could maintain RAAS inhibitor therapy and, in some studies, were not required to limit dietary K þ. There may also be a role for these agents in preventing hyperkalemia in patients receiving hemodialysis. Thus, K þ-binding agents may allow patients with CKD at risk for hyperkalemia to optimize RAAS inhibitor therapy, receive benefits of a K þ-rich diet, and experience improved hemodialysis outcomes. Additional longterm studies are necessary to confirm these effects.

show abstract

“…The IBM MarketScan Commercial and Medicare-Supplemental Claims database has been used in multiple studies for the assessment of prevalence, clinical burden, and economic burden of hyperkalemia. 8,15,16 The multiple strengths of this database made it the most suitable database for the present study. For example, all medical claims covering inpatient, outpatient, and emergency room visits were recorded during each patient's eligibility period, making it feasible to capture all of a patient's HRU and costs.…”

Section: Data Sourcementioning

confidence: 99%

Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations

Betts

Woolley

et al. 2020

Kidney International Reports

Self Cite

View full text Add to dashboard Cite

Introduction: Limited evidence is available regarding the postdischarge economic and readmission burdens of hyperkalemia. Methods: Using the IBM MarketScan Commercial and Medicare-Supplemental Claims database (January 1, 2010-December 31, 2014), adult patients with a hospitalization with a hyperkalemia diagnosis (ICD-9-CM 276.7, hyperkalemia cohort) were 1:1 matched with patients with a hospitalization without evidence of hyperkalemia (nonhyperkalemia cohort) on age, chronic kidney disease stage, heart failure, dialysis, reninangiotensin-aldosterone system inhibitor use, and major diagnostic categories of the hospitalization. Allcause health care costs and health care resource utilization measures were compared between cohorts during the 1-year postdischarge period. Postdischarge readmission and length of stay (LOS) were compared between hyperkalemia-related hospitalizations from the hyperkalemia cohort and matched hospitalizations unrelated to hyperkalemia from the nonhyperkalemia cohort.

show abstract

The prevalence of hyperkalemia in the United States

Cited by 80 publications

References 28 publications

Prevalence and economic burden of hyperkalemia in the United States Medicare population

Prevalence and economic burden of hyperkalemia in the United States Medicare population

Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis

Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations

Contact Info

Product

Resources

About